Preferred Treatment of Type 1.5 Diabetes

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

rosiglitazone

Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.

DRUG

glyburide

Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.

Trial Locations (1)

98108

DVA Puget Sound Health Care System, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seattle Institute for Biomedical and Clinical Research

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Washington

OTHER

NCT00194896 - Preferred Treatment of Type 1.5 Diabetes | Biotech Hunter | Biotech Hunter